"GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "RIV/00064173:_____/11:#0000169!RIV13-MZ0-00064173" . . "No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma"@en . "Leukemia Research" . . "Havr\u00E1nek, Ond\u0159ej" . "3"^^ . . "M\u00F3cikov\u00E1, Heidi" . "35" . . . . "I, S, Z(MSM0021620808), Z(MSM0021620813)" . . . "10.1016/j.leukres.2011.04.001" . . . . "8" . . . . . "No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma" . "2"^^ . "RIV/00064173:_____/11:#0000169" . "No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma" . "TP53 gene (p53),; Arg72Pro polymorphism (R72P); Non-Hodgkin lymphoma; Hodgkin lymphoma; Genetic predispositio"@en . . "216109" . . "No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma"@en . . "The role of the TP53 gene's R72P polymorphism in non-Hodgkin lymphoma (NHL) has been analyzed in several studies but it has not been studied in Hodgkin lymphoma (HL). We have evaluated the role of R72P in 340 NHL and 298 HL patients. There was no difference in the R72P frequency between analyzed lymphoma cases and 749 controls. We found no association of R72P with the risk of NHL and HL development [OR(ArgPro/ProPro) = 0.9 (95% CI 0.7-1.2) and 1.2 (95% CI 0.9-1.5), respectively] or with survival. Our results support the evidence that R72P is not a prognostic factor in Caucasian NHL patients, and they indicate its irrelevance for HL development or prognosis." . "8"^^ . . "\u0160pa\u010Dek, Martin" . . "0145-2126" . "000292735300026" . "[D2874524B0DB]" . . "The role of the TP53 gene's R72P polymorphism in non-Hodgkin lymphoma (NHL) has been analyzed in several studies but it has not been studied in Hodgkin lymphoma (HL). We have evaluated the role of R72P in 340 NHL and 298 HL patients. There was no difference in the R72P frequency between analyzed lymphoma cases and 749 controls. We found no association of R72P with the risk of NHL and HL development [OR(ArgPro/ProPro) = 0.9 (95% CI 0.7-1.2) and 1.2 (95% CI 0.9-1.5), respectively] or with survival. Our results support the evidence that R72P is not a prognostic factor in Caucasian NHL patients, and they indicate its irrelevance for HL development or prognosis."@en . .